X

Trial Profile

Phase I-II Study of the Combination Vemurafenib Plus Cobimetinib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 10 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cobimetinib (Primary) ; Peginterferon (Primary) ; Vemurafenib (Primary)
Indications Malignant melanoma
Focus Adverse reactions
Acronyms VEMUPLINT

Most Recent Events

10 Mar 2022 This trial has been discontinued, according to European Clinical Trials Database record.
07 Jun 2019 Status changed from recruiting to completed.
18 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com